GeoVax Labs Inc. (NASDAQ:GOVX) Short Interest Up 139.4% in July

GeoVax Labs Inc. (NASDAQ:GOVX) saw a significant increase in short interest in the month of July. As of July 15th, there was short interest totaling 150,485 shares, an increase of 139.4% from the June 30th total of 62,850 shares. Based on an average trading volume of 266,107 shares, the short-interest ratio is presently 0.6 days. Approximately 4.4% of the shares of the company are short sold.

Analysts Set New Price Targets

GOVX has been the topic of several recent research reports. Wall Street Zen raised GeoVax Labs from a “sell” rating to a “hold” rating in a report on Sunday, June 21st. D. Boral Capital reaffirmed a “hold” rating on shares of GeoVax Labs in a research report on Thursday, April 16th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of GeoVax Labs in a research note on Friday, July 17th. One analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, GeoVax Labs has a consensus rating of “Reduce” and an average price target of $150.00.

GeoVax Labs Trading Down 3.9%

NASDAQ GOVX opened at $0.70 on Thursday. The company has a 50-day moving average price of $1.47 and a two-hundred day moving average price of $1.77. GeoVax Labs has a 52 week low of $0.64 and a 52 week high of $20.62. The stock has a market cap of $2.42 million, a price-to-earnings ratio of -0.04 and a beta of 3.68.

GeoVax Labs (NASDAQ:GOVX) last released its quarterly earnings results on Monday, July 27th. The company reported ($0.97) earnings per share for the quarter, beating analysts’ consensus estimates of ($2.16) by $1.19. As a group, equities research analysts expect that GeoVax Labs will post -8.69 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. Renaissance Technologies LLC bought a new position in shares of GeoVax Labs in the fourth quarter worth $104,000. Jane Street Group LLC acquired a new position in shares of GeoVax Labs during the fourth quarter valued at $99,000. Armistice Capital LLC bought a new stake in shares of GeoVax Labs during the third quarter valued at about $253,000. Finally, HRT Financial LP bought a new stake in shares of GeoVax Labs during the fourth quarter valued at about $31,000. Institutional investors and hedge funds own 6.09% of the company’s stock.

GeoVax Labs Company Profile

GeoVax Labs, Inc is a clinical-stage biotechnology company focused on the development of novel vaccines and immunotherapies against infectious diseases. Leveraging a proprietary Modified Vaccinia Ankara (MVA) viral vector platform, GeoVax aims to induce robust and durable immune responses by expressing virus-like particles (VLPs) in vaccinated individuals. The company’s pipeline encompasses vaccine candidates for HIV, Ebola, Lassa, Zika, MERS and emerging coronaviruses, reflecting a commitment to addressing high-priority global public health threats.

The cornerstone of GeoVax’s technology is its MVA-VLP platform, which combines the safety profile of a non-replicating poxvirus vector with the potent antigen presentation of VLPs.